TIDMREDX
Redx Pharma plc
12 May 2023
REDX PHARMA PLC
("Redx" or the "Company")
Redx's Discovery of Pirtobrutinib Recognised with Unveiling of
Commemorative Plaque at Alderley Park
Pirtobrutinib, originally discovered by Redx scientists,
received FDA approval in January 2023
Pirtobrutinib is one of five molecules originating from the Redx
drug discovery platform that have progressed into clinical
development
Alderley Park, UK, 12 May 2023 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of cancer and fibrotic disease confirms that a
commemorative plaque has been unveiled by Bruntwood SciTech at
their Alderley Park campus, where Redx is headquartered, in
recognition of the team's discovery of pirtobrutinib(1) , the
active pharmaceutical ingredient (API) in Eli Lilly's ("Lilly"
NYSE:LLY) Jaypirca(TM)(2) .
On 27 January 2023, Lilly announced the approval of
pirtobrutinib by the US Food and Drug Administration (FDA) for the
treatment of adult patients with relapsed or refractory mantle cell
lymphoma (MCL) after at least two lines of systemic therapy,
including a BTK inhibitor. More recently, in April 2023, the drug
also received a positive opinion from the European Committee for
Medicinal Products for Human Use (CHMP). Pirtobrutinib, is a highly
selective kinase inhibitor and is the first and only FDA approved
non-covalent (reversible) BTK inhibitor available.
Pirtobrutinib, formerly known as RXC005, was discovered by Dr.
Nicolas Guisot, Vice President, Drug Discovery and the team at
Redx. RXC005 was successfully nominated as a drug candidate by the
Company in October 2016 and was progressed through early
development, before being divested to Loxo Oncology in July
2017.
Steve Bates OBE, Chief Executive Officer, UK BioIndustry
Association, commented: "The approval of pirtobrutinib is a
testament to the potential of the UK biotech industry to discover
important new treatments for unmet medical needs. The team at Redx
should be incredibly proud to have originated a molecule that has
made it to market given that fewer than 5% of preclinical projects
currently achieve this milestone. It also serves to highlight that
an FDA approval is the culmination of years of work, requiring
significant investment, which often forces the UK biotech community
to secure partnerships and investment from outside the UK so their
research can become reality. With its world-class innovation
capabilities, of which pirtobrutinib offers a shining example, the
UK can be a real force in the global biotech market and greater
financial and political support from within will help ensure more
of the ultimate returns are captured by the UK economy."
Redx has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
potential best-in-class, or first-in-class therapeutics.
Pirtobrutinib is one of five molecules originating from the Redx
drug discovery platform that are currently approved or in a
clinical phase of development. The Company's lead asset, RXC007, a
next-generation selective ROCK2 inhibitor, is currently in Phase 2a
clinical trials for idiopathic pulmonary fibrosis (IPF) and also
has potential in a number of other fibrotic indications. Redx is
also developing RXC004 which is in a phase 2 programme in
Wnt-ligand driven cancer, expected to report at the end of 2023,
and is progressing a potential new novel treatment for
fibrostenotic Crohn's disease, RXC008, where no therapeutic
treatment options currently exist, towards a Phase 1 clinical trial
expected to commence in 2024.
Lisa Anson, Chief Executive Officer, Redx Pharma, commented: "As
the originators of pirtobrutinib, the approval of Jaypirca(TM) by
the US FDA demonstrates the world-class capabilities of Redx's
scientists placing the team amongst the few UK biotechs who have
successfully discovered an FDA approved drug. This achievement
showcases what the UK biotech industry is capable of and the need
to nurture and support innovation. We are proud to be headquartered
at Alderley Park, the largest single-site life science park in the
UK, and delighted that this achievement has been commemorated with
the unveiling of a plaque on the Park's 'Wall of Discovery'. I
would particularly like to congratulate Dr. Nicolas Guisot, Vice
President, Drug Discovery and Dr. Richard Armer, Chief Scientific
Officer, both of whom were instrumental in the discovery of
pirtobrutinib, along with the team at Redx. We look forward to
continuing to deliver on our vision of discovering targeted
medicines that impact patients."
At the event which took place last night, Redx CEO, Lisa Anson,
was joined by CSO, Dr. Richard Armer, and Dr. Kath Mackay, Director
of Life Sciences, Bruntwood SciTech, who all spoke prior to the
unveiling of the plaque. Also, in attendance were a number of the
Redx scientific team and peers from across the UK Northwest biotech
industry. Dr. Nicolas Guisot, VP, Drug Discovery at Redx and
discoverer of pirtobrutinib, was invited to unveil the
commemorative plaque, the first since Bruntwood SciTech took
ownership of the premises in 2014.
( L-R: Lisa Anson Chief Executive Officer, Redx Pharma, Dr.
Nicolas Guisot, VP Drug Discovery, Redx Pharma, Dr. Kath Mackay,
Director of Life Sciences, Bruntwood SciTech, Dr. Richard Armer,
Chief Scientific Officer, Redx Pharma)
1 the asset was subsequently sold outright to Loxo Oncology, now
part of Eli Lilly, Redx has no remaining economic interest
2 Jaypirca(TM) is a trademark owned or licensed by Eli Lilly and
Company, its subsidiaries, or affiliates.
For further information, please contact:
Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, targeted therapeutics for the treatment of cancer and
fibrotic disease and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor RXC007, is in development
for interstitial lung disease being evaluated in a Phase 2a trial
for idiopathic pulmonary fibrosis (IPF) with topline data expected
in Q1 2024. Redx's lead oncology product candidate, the Porcupine
inhibitor RXC004, is being developed as a targeted treatment for
Wnt-ligand dependent cancers, is expected to report Phase 2 data in
combination with anti-PD-1 by end 2023. Redx's third drug
candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment
of fibrostenotic Crohn's disease, is progressing towards a CTA
application in H2 2023.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its two wholly-owned clinical-stage product candidates and
rapidly expanding pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, REDX08608, LOXO-305),
a non-covalent (reversible) BTK inhibitor now approved by the US
FDA for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFSTERIFLIV
(END) Dow Jones Newswires
May 12, 2023 04:51 ET (08:51 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Dec 2023 to Dec 2024
